DK1490492T3 - Hybridt hepatocytvækstfaktorgen med höj ekspressionseffektivitet af to heterotyper af hepatocytvækstfaktor - Google Patents
Hybridt hepatocytvækstfaktorgen med höj ekspressionseffektivitet af to heterotyper af hepatocytvækstfaktorInfo
- Publication number
- DK1490492T3 DK1490492T3 DK03744561T DK03744561T DK1490492T3 DK 1490492 T3 DK1490492 T3 DK 1490492T3 DK 03744561 T DK03744561 T DK 03744561T DK 03744561 T DK03744561 T DK 03744561T DK 1490492 T3 DK1490492 T3 DK 1490492T3
- Authority
- DK
- Denmark
- Prior art keywords
- growth factor
- hepatocyte growth
- gene
- heterotypes
- high expression
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020020015074A KR100562824B1 (ko) | 2002-03-20 | 2002-03-20 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
PCT/KR2003/000548 WO2003078568A2 (en) | 2002-03-20 | 2003-03-20 | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1490492T3 true DK1490492T3 (da) | 2008-03-17 |
Family
ID=28036130
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK03744561T DK1490492T3 (da) | 2002-03-20 | 2003-03-20 | Hybridt hepatocytvækstfaktorgen med höj ekspressionseffektivitet af to heterotyper af hepatocytvækstfaktor |
Country Status (14)
Country | Link |
---|---|
US (5) | US7812146B2 (da) |
EP (1) | EP1490492B1 (da) |
JP (1) | JP4057537B2 (da) |
KR (1) | KR100562824B1 (da) |
CN (1) | CN100378219C (da) |
AT (1) | ATE380826T1 (da) |
AU (1) | AU2003210053A1 (da) |
BR (1) | BRPI0303570B8 (da) |
DE (1) | DE60318026T2 (da) |
DK (1) | DK1490492T3 (da) |
ES (1) | ES2298538T3 (da) |
HK (1) | HK1080895A1 (da) |
PT (1) | PT1490492E (da) |
WO (1) | WO2003078568A2 (da) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100562824B1 (ko) | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
KR20080082629A (ko) * | 2005-11-10 | 2008-09-11 | 리셉터 바이오로직스 인크 | 간세포 성장인자 인트론 융합 단백질 |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
CA2720611C (en) * | 2008-04-09 | 2016-07-12 | Viromed Co., Ltd. | Lyophilized dna formulations for enhanced expression of plasmid dna |
EP2216399A1 (en) | 2009-01-30 | 2010-08-11 | Université de la Méditerranée | Human soluble CD146, preparation and uses thereof |
CN102120047A (zh) * | 2010-01-11 | 2011-07-13 | 上海优益绩国际贸易有限公司 | 血运重建基因药物靶向投递缓释支架 |
MX2016005006A (es) | 2013-10-22 | 2016-07-14 | Viromed Co Ltd | Composicion para prevenir a tratar la esclerosis lateral amiotrofica usando dos o mas isoformas del factor de crecimiento de hepatocito. |
WO2016048105A1 (ko) * | 2014-09-26 | 2016-03-31 | 주식회사 바이로메드 | 간세포 성장인자 및 기질세포 유발인자1알파를 이용한 말초동맥질환의 예방 또는 치료용 조성물 |
WO2017135795A1 (ko) * | 2016-02-04 | 2017-08-10 | 주식회사 에스엘바이젠 | 간세포성장인자를 발현하는 중간엽줄기세포 및 이의 용도 |
CA3086046C (en) * | 2017-12-29 | 2023-02-21 | Helixmith Co., Ltd. | Adeno-associated virus (aav) vector having hybrid hgf gene introduced thereto |
KR102245539B1 (ko) | 2018-02-12 | 2021-04-29 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
CN108611367B (zh) * | 2018-04-24 | 2019-11-19 | 北京诺思兰德生物技术股份有限公司 | 一类通过质粒载体介导的基因治疗重组载体 |
CN112533642A (zh) * | 2018-05-17 | 2021-03-19 | 赫利世弥斯株式会社 | 治疗与化疗诱发的周围神经病变相关的神经性疼痛 |
CA3106078A1 (en) * | 2018-07-17 | 2020-01-23 | Junghun Lee | Treatment of neuropathy with dna constructs expressing igf-1 isoforms |
US11554179B2 (en) | 2018-07-19 | 2023-01-17 | Helixmith Co., Ltd | Lyophilized pharmaceutical compositions for naked DNA gene therapy |
CN110747214B (zh) * | 2019-03-13 | 2021-12-31 | 深圳市臻质医疗科技有限公司 | DNA片段、具有长效表达和细胞特异性结合能力的mRNA-抗体融合分子及其制备方法 |
KR20210035126A (ko) | 2021-03-18 | 2021-03-31 | 주식회사 지앤피바이오사이언스 | 코어-쉘 구조의 마이크로 입자를 유효성분으로 포함하는 성장인자 유전자 발현 증가용 조성물 |
KR20220135215A (ko) * | 2021-03-29 | 2022-10-06 | 주식회사 헬릭스미스 | 샤르코-마리-투스병 예방 또는 치료용 약제학적 조성물 |
US20230212603A1 (en) * | 2021-10-06 | 2023-07-06 | G&P Bioscience Co., Ltd. | Development of optimized recombinant expression construct |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ232813A (en) * | 1989-03-10 | 1992-08-26 | Snow Brand Milk Products Co Ltd | Human fibroblast glycoprotein, cell differentiation, blood vessel endothelial cell growth factor, cellular immunology inforcing factor of 78 or 74 thousand daltons plus or minus two thousand daltons |
US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
US6673776B1 (en) * | 1989-03-21 | 2004-01-06 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human |
US5693622A (en) * | 1989-03-21 | 1997-12-02 | Vical Incorporated | Expression of exogenous polynucleotide sequences cardiac muscle of a mammal |
CA2022752C (en) * | 1989-08-11 | 1998-07-07 | Naomi Kitamura | Hepatic parenchymal cell growth factor, gene encoding the same, process for producing the factor, and transformants producing the factor |
US6706694B1 (en) * | 1990-03-21 | 2004-03-16 | Vical Incorporated | Expression of exogenous polynucleotide sequences in a vertebrate |
EP0539590B1 (en) * | 1990-07-13 | 1999-03-31 | Snow Brand Milk Products Co., Ltd. | Plasmid containing dna which codes for the amino acid sequence of tcf-ii, transformed cell, and production of physiologically active substance by using the same |
US5661133B1 (en) * | 1991-11-12 | 1999-06-01 | Univ Michigan | Collateral blood vessel formation in cardiac muscle by injecting a dna sequence encoding an angiogenic protein |
US5837676A (en) * | 1993-10-18 | 1998-11-17 | Long Island Jewish Medical Center | Use of scatter factor to enhance angiogenesis |
US6498144B1 (en) * | 1993-10-18 | 2002-12-24 | North Shore - Long Island Jewish Research Institute | Use of scatter factor to enhance angiogenesis |
US5652225A (en) * | 1994-10-04 | 1997-07-29 | St. Elizabeth's Medical Center Of Boston, Inc. | Methods and products for nucleic acid delivery |
US20030148968A1 (en) | 1995-02-28 | 2003-08-07 | Hammond H. Kirk | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
WO1997007824A1 (fr) * | 1995-08-29 | 1997-03-06 | Sumitomo Pharmaceuticals Co., Ltd. | Medicament comprenant le gene hgf |
US5830879A (en) * | 1995-10-02 | 1998-11-03 | St. Elizabeth's Medical Center Of Boston, Inc. | Treatment of vascular injury using vascular endothelial growth factor |
US6121246A (en) * | 1995-10-20 | 2000-09-19 | St. Elizabeth's Medical Center Of Boston, Inc. | Method for treating ischemic tissue |
EA005157B1 (ru) | 1997-05-06 | 2004-12-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Методы и составы для лечения сердечной недостаточности и вентрикулярной коррекции путем доставки in vivo ангиогенных трансгенов |
JPH11246433A (ja) | 1998-03-03 | 1999-09-14 | Sumitomo Pharmaceut Co Ltd | 心筋梗塞治療剤 |
US20040228834A1 (en) * | 1998-03-09 | 2004-11-18 | Jeffrey Isner | Compositions and methods for modulating vascularization |
WO1999045775A1 (en) | 1998-03-09 | 1999-09-16 | St. Elizabeth's Medical Center | Compositions and methods for modulating vascularization |
WO2000007615A1 (fr) * | 1998-08-05 | 2000-02-17 | Sumitomo Pharmacueticals Co., Ltd. | Preparations destinees a l'administration d'un facteur de croissance des hepatocytes |
CA2356701C (en) * | 1999-10-29 | 2011-02-15 | Ryuichi Morishita | Gene therapy for diabetic ischemic disease |
JP2003513942A (ja) | 1999-11-05 | 2003-04-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | インビボ遺伝子送達による心血管疾患を処理するための技術および組成物 |
CN1142272C (zh) * | 2000-02-02 | 2004-03-17 | 中国人民解放军军事医学科学院百环生物医学研究中心 | 携带人肝细胞生长因子基因的重组腺病毒的用途 |
ATE530197T1 (de) * | 2000-06-27 | 2011-11-15 | Anges Mg Inc | Medizinische zusammensetzungen zur angiogenese- therapie |
CA2433936A1 (en) * | 2001-01-23 | 2002-08-22 | Boston Scientific Corporation | Localized myocardial injection method for treating ischemic myocardium |
KR100562824B1 (ko) * | 2002-03-20 | 2006-03-23 | 주식회사 바이로메드 | 유전자 발현효율이 높으며 간세포 성장인자의 두 가지이형체를 동시에 발현하는 하이브리드 간세포 성장인자유전자 |
AU2006244639A1 (en) * | 2005-03-31 | 2006-11-16 | Mytogen, Inc. | Treatment for heart disease |
US20090202606A1 (en) * | 2008-01-25 | 2009-08-13 | Viromed Co., Ltd. | Treatment and Prevention of Cardiac Conditions Using Two or More Isoforms of Hepatocyte Growth Factor |
CA2720611C (en) | 2008-04-09 | 2016-07-12 | Viromed Co., Ltd. | Lyophilized dna formulations for enhanced expression of plasmid dna |
-
2002
- 2002-03-20 KR KR1020020015074A patent/KR100562824B1/ko active IP Right Grant
-
2003
- 2003-03-20 AU AU2003210053A patent/AU2003210053A1/en not_active Abandoned
- 2003-03-20 DE DE60318026T patent/DE60318026T2/de not_active Expired - Lifetime
- 2003-03-20 WO PCT/KR2003/000548 patent/WO2003078568A2/en active IP Right Grant
- 2003-03-20 EP EP03744561A patent/EP1490492B1/en not_active Expired - Lifetime
- 2003-03-20 DK DK03744561T patent/DK1490492T3/da active
- 2003-03-20 BR BRPI0303570A patent/BRPI0303570B8/pt not_active IP Right Cessation
- 2003-03-20 AT AT03744561T patent/ATE380826T1/de active
- 2003-03-20 JP JP2003576563A patent/JP4057537B2/ja not_active Expired - Lifetime
- 2003-03-20 PT PT03744561T patent/PT1490492E/pt unknown
- 2003-03-20 CN CNB038065347A patent/CN100378219C/zh not_active Expired - Lifetime
- 2003-03-20 ES ES03744561T patent/ES2298538T3/es not_active Expired - Lifetime
-
2004
- 2004-09-20 US US10/944,277 patent/US7812146B2/en active Active
-
2006
- 2006-01-17 HK HK06100717A patent/HK1080895A1/xx not_active IP Right Cessation
-
2007
- 2007-12-14 US US11/957,170 patent/US7838505B2/en not_active Expired - Lifetime
-
2009
- 2009-12-31 US US12/650,860 patent/US7745174B2/en not_active Ceased
-
2010
- 2010-10-20 US US12/908,765 patent/US8338385B2/en not_active Expired - Lifetime
-
2017
- 2017-07-05 US US15/642,307 patent/USRE48404E1/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
KR20030075718A (ko) | 2003-09-26 |
WO2003078568A2 (en) | 2003-09-25 |
BRPI0303570B1 (pt) | 2018-04-24 |
US20050079581A1 (en) | 2005-04-14 |
CN1643149A (zh) | 2005-07-20 |
ES2298538T3 (es) | 2008-05-16 |
KR100562824B1 (ko) | 2006-03-23 |
WO2003078568A3 (en) | 2003-11-27 |
DE60318026D1 (de) | 2008-01-24 |
ATE380826T1 (de) | 2007-12-15 |
BR0303570A (pt) | 2005-07-19 |
HK1080895A1 (en) | 2006-05-04 |
EP1490492A2 (en) | 2004-12-29 |
US20120010273A1 (en) | 2012-01-12 |
US7838505B2 (en) | 2010-11-23 |
JP4057537B2 (ja) | 2008-03-05 |
US8338385B2 (en) | 2012-12-25 |
JP2005520512A (ja) | 2005-07-14 |
US20090131350A1 (en) | 2009-05-21 |
PT1490492E (pt) | 2008-03-25 |
EP1490492A4 (en) | 2006-05-31 |
USRE48404E1 (en) | 2021-01-26 |
BRPI0303570B8 (pt) | 2021-05-25 |
US7745174B2 (en) | 2010-06-29 |
EP1490492B1 (en) | 2007-12-12 |
CN100378219C (zh) | 2008-04-02 |
DE60318026T2 (de) | 2008-11-20 |
AU2003210053A8 (en) | 2003-09-29 |
US20100105878A1 (en) | 2010-04-29 |
US7812146B2 (en) | 2010-10-12 |
AU2003210053A1 (en) | 2003-09-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1080895A1 (en) | Hybrid hepatocyte growth factor gene having high expression efficiency of two heterotypes of hepatocyte growth factor | |
EA200600746A1 (ru) | Конструкции нуклеиновых кислот | |
EA200401591A1 (ru) | Керамические аноды и способ их изготовления | |
ATE462000T1 (de) | Verfahren zur herstellung von l-arginin, l- ornithin oder l-citrullin | |
DK1658365T3 (da) | Fremgangsmåde til genkloning af produktionsceller | |
BRPI0618488A2 (pt) | proteìnas de fusão de ìntron de fator de crescimento de hepatócito | |
ATE291616T1 (de) | Neue carbonyl-reduktase, gen davon und verfahren der anwendung derselben | |
MY140680A (en) | Hepatitis c virus inhibitors | |
DE60144145D1 (de) | Subtilisin-variante | |
DK2251353T3 (da) | Homogene fremstillinger af IL-29 | |
IS8448A (is) | Lifrarbólgu C-veirutálmar | |
ATE430589T1 (de) | Wasserbehandlung zur kontrolle von biobewuchs mittels stabilisierter bromlösungen | |
EA200701643A1 (ru) | Конструкции нуклеиновых кислот | |
BR0313559A (pt) | Método para o cultivo de células primárias e para a amplificação de vìrus sob condições isentas de soro | |
ATE518960T1 (de) | Gentechnisch hergestellte zinkfingerproteine zur regulation der genexpression | |
DK1501936T3 (da) | Familie af cytokin-proteiner | |
ATE260296T1 (de) | Anti-gefrier proteine, deren herstellung und verwendung | |
DK1147088T3 (da) | 6-arylphenanthridiner med PDE-IV-inhiberende aktivitet | |
ATE365807T1 (de) | Hepatitis b virus vektoren für gentherapie | |
DE69939586D1 (de) | Inhibitoren für die gefässneubildung | |
HUP0203543A2 (hu) | Eljárás aril-triazolinonok előállítására és új intermedierek az eljáráshoz | |
DE60007991D1 (de) | Verwendung des proteins uk 114 zur verhinderung der abstossung eines transplantierten organs | |
DE60312497D1 (de) | Verwendung von protein maba (fabg1) aus mycobacterium tuberculosis zur herstellung und nachweis von antibiotika | |
DE50006815D1 (de) | Verfahren zur herstellung antitumoraler th1-zellen | |
DK1794294T3 (da) | Rekombinant carboxypeptidase B |